Currently, biomarkers, such as neutrophil-to-lymphocyte ratio, gut microbiota, tumor-infiltrating lymphocytes, etc., are used for predicting immunotherapy’s efficacy in non-small cell lung cancer (NSCLC) [17, 18], and PD-L1 and tumor mutation burden (TMB) remain the most widely used biomarkers approved by the Food and Drug Administration (FDA). The gene discussed is CD274; the disease is non-small cell lung carcinoma.